Journal of Crohn s and Colitis

Statin use is independently associated with reduced progression to stricture formation in two PS-matched large and diverse cohorts of patients with CD.

We provide the first expert-endorsed temporal framework for outcome assessment in RWE studies of CD. Standardized measurement timing can enhance study comparability and methodological rigor, supporting more consistent interpretation of real-world data. Claims are limited to framework development and do not extend to direct clinical or regulatory impact.

VDZ achieved clinical response of active EIMs in nearly one-third of patients after 3 months. Although infrequent, VDZ may exacerbate inactive EIMs and induce de novo EIMs during therapy, potentially leading to treatment discontinuation.

Transcriptomic profiling of rectal fecal aspirates reliably detects small bowel inflammation and identifies specific immune pathways in asymptomatic CD. The resulting models offer potential biomarkers for CD diagnosis and monitoring.

Filgotinib response was associated with normalization of the cellular frequency and gene expression levels of B cells and phagocytic mononuclear cells in UC patients, resulting in immune profiles resembling those of healthy controls.

IUS correlated strongly with endoscopy in pediatric Crohn's disease over 1 year, with increased BWT being associated with a higher risk of ileocecal resection and not achieving remission. Thickened (inflamed) bowel became significantly thinner as soon as 1 month. BWT in pediatric patients in remission was significantly lower (≤2.5 mm) than in adults (≤3-4 mm).

NCT04673357.

Ferritin showed the strongest association with hepcidin across IBD, but regulation differed by disease. In UC, lower hepcidin levels were associated with intestinal inflammatory activity measured by fecal calprotectin, whereas in CD, higher hepcidin levels were associated with systemic inflammation despite iron deficiency. These findings highlight hepcidin's potential as a biomarker linking iron …

In this population-based real-world medication study, we observed that 5-ASA remains the mainstay of treatment for UC, whereas advanced therapies dominate long-term treatment for CD. Of note, half of patients did not receive any medical treatment in the tenth year after diagnosis.

Newly diagnosed patients with IBD experienced significant psychological challenges compared with the NGP. Early identification of anxiety and depression may enable targeted interventions.

Global IBD knowledge and awareness remain inadequate and uneven across regions and domains. Updated, culturally appropriate and adaptable assessment tools and multidisciplinary, technology-enabled educational strategies are needed to enhance IBD literacy.

CD is associated with heightened CRC and SBC risks, varying by disease location. These findings underscore the need for tailored cancer screening and further research into the impact of environmental and genetic factors on cancer risk in CD patients.

Autoimmune blistering diseases (AIBDs) may occur as adverse effects of various therapies, including biologics. Data on their association with IL-23 inhibitors in ulcerative colitis (UC) remain limited. We report the case of a 59-year-old man with UC who developed pruritic cutaneous bullae emerging within days following mirikizumab infusion. Histopathological examination and direct immunofluoresce…

Together, our findings suggest that the TWEAK/NF-κB/STAT3 axis represents an attractive target to tune inflammatory stroma/monocyte crosstalk.

There is an unmet need to generate novel local therapies that achieve long-lasting fistula closure. To facilitate their development, the delineation of host and microbial pathways contributing to PFCD pathogenesis and research in drug delivery systems are needed.

Significant heterogeneity in trial design, populations, and outcome reporting limits the predictive value of placebo-controlled trials. Randomized head-to-head trials remain essential for optimizing IBD therapeutic strategies.

Colonic FMT is a more effective delivery route than nasogastric administration. Clinical response is driven by the engraftment of immunomodulatory bacteria that restore a healthy host-microbe dialogue, providing rationale for developing targeted microbial therapeutics.

This IOIBD consensus supports the integration of AI/ML into central reading for IBD clinical trials to improve objectivity, efficiency, and consistency, while maintaining human oversight. Further research should address validation, regulatory frameworks, and multimodal integration to enable broader adoption in both trials and clinical practice.